8-KRegulation FDOther EventsExhibits & Filings

Cencora, Inc. 8-K Report, Regulation FD Disclosure (Nov 8, 2024)

Filed November 8, 2024For Securities:COR

Summary

Cencora, Inc. (COR) has announced a significant strategic move through a definitive agreement to acquire Retina Midco, Inc. ("Retina Consultants of America" or "RCA"), a leading management services organization for retina specialists. This acquisition, valued at approximately $4.6 billion on an enterprise value basis, is expected to be funded through a combination of existing cash and new debt financing, with the company securing $3.3 billion in bridge financing commitments. The transaction is structured with a cash outlay at closing of roughly $4.3 billion, after accounting for equity rollover by RCA's affiliated practices, physicians, and management, as well as planned cash capitalization by Cencora and transaction expenses. Cencora anticipates holding approximately 85% ownership of RCA post-closing, with an additional potential of up to $500 million in contingent consideration tied to future business performance. This acquisition represents a substantial investment and strategic expansion for Cencora into the high-growth area of specialized ophthalmology services. Investors should note the significant cash expenditure and increased leverage anticipated. The deal is subject to customary closing conditions, including regulatory approvals, and includes forward-looking statements that highlight potential risks and uncertainties, such as the ability to achieve expected benefits, synergies, and operational efficiencies, as well as potential business disruptions and challenges in retaining key personnel. Cencora encourages a review of its SEC filings for a comprehensive understanding of these risks.

Key Highlights

  • 1Cencora, Inc. (COR) entered into a definitive agreement to acquire Retina Midco, Inc. ("Retina Consultants of America" or "RCA").
  • 2The acquisition is valued at an enterprise value of approximately $4.6 billion, subject to customary adjustments.
  • 3Cencora's expected cash outlay at closing is approximately $4.3 billion, after considering equity rollover and other factors.
  • 4The company expects to hold approximately 85% ownership of RCA post-closing.
  • 5An additional $500 million in contingent consideration may be paid subject to achieving predefined business objectives in fiscal years 2027 and 2028.
  • 6The transaction is expected to be funded by cash on hand and new debt financing, with $3.3 billion in bridge financing commitments secured.
  • 7The acquisition is subject to customary closing conditions, including regulatory approvals.

Frequently Asked Questions

The primary purpose of this acquisition is to expand Cencora's presence into the specialized field of retina care by acquiring Retina Consultants of America (RCA), a leading management services organization (MSO) for retina specialists. This aligns with strategic growth initiatives in specialized healthcare services.

Cencora plans to fund the acquisition through a combination of its existing cash on hand and new debt financing. The company has already secured $3.3 billion in bridge financing commitments to support the transaction.

The acquisition involves a significant cash outlay of approximately $4.3 billion at closing, along with potential future contingent payments of up to $500 million. This will also increase Cencora's debt leverage, as evidenced by the bridge financing. Investors should monitor Cencora's financial statements for the impact on its balance sheet and cash flow.

Yes, the agreement includes provisions for potential contingent consideration of up to $500 million in aggregate. This amount is tied to the successful completion of certain predefined business objectives within fiscal years 2027 and 2028.